Your AI-Trained Oncology Knowledge Connection!

New Treatment Options for DLBCL: Impact on Sequencing Therapeutic Choices : Episode 1

Opinion

Video

December 19, 2023

Overview of First-Line Treatment in Diffuse Large B-Cell Lymphoma

Author(s):

Sonali Smith, MD,Krish Patel, MD

Key opinion leaders on diffuse large B-cell lymphoma management provide a review first-line treatment options.

Now Viewing

EP: 1.Overview of First-Line Treatment in Diffuse Large B-Cell Lymphoma

EP: 2.Evolving Practice Standards and Disease Progression Beyond Frontline Therapy for Patients with DLBCL

EP: 3.Treatment Selection in Second Line R/R DLBCL

EP: 4.Tafasitamab and Lenalidomide for R/R DLBCL

EP: 5.Real-World Outcomes of Tafasitamab-Lenalidomide for Patients with R/R DLBCL

EP: 6.The Role of CAR T-Cell Therapy in R/R DLBCL

EP: 7.Data Updates: CAR T in the ZUMA-7 and TRANSFORM Trials for R/R DLBCL

EP: 8.Clinical Perspectives of CAR T in R/R Diffuse Large B-Cell Lymphoma

EP: 9.Navigating Toxicities in CAR T-Cell Therapy in R/R DLBCL

EP: 10.Relapsed/Refractory DLBCL: Therapeutic Options in the Third Line Setting

EP: 11.Bispecifics for Third Line Therapy of R/R DLBCL

EP: 12.R/R DLBCL: Safety Considerations for Bispecific Antibodies

EP: 13.Treatment Sequencing of Later Line Therapies in R/R DLBCL

EP: 14.Additional Data Updates from ASH 2023

EP: 15.Future Outlooks in the Treatment of R/R DLBCL

Stay up to date on the most recent and practice-changing oncology data

Subscribe Now!

Latest CME

View All

Video

Community Oncology Connections™: Case Discussions in TNBC…Navigating the Latest Advances and Impact of Disparities in Care | North Carolina

Apr 17th 2025 - May 23rd 2025

online-activity

Video

Community Oncology Connections™: Community Oncologists’ Role in Selecting Optimal Oral SERD Treatment for HR+/HER2– Breast Cancer | Minnesota

Apr 17th 2025 - May 23rd 2025

online-activity

Video

18th Annual Interdisciplinary Prostate Cancer Congress® and Other Genitourinary Malignancies

Apr 8th 2025 - May 14th 2025

online-activity

Latest Conference Coverage

Overview of iMMagine-1 Trial: Phase 2 Registrational Study of Anitocabtagene Autoleucel for the Treatment of R/R MM

Application of Real-World Evidence in Selecting CAR T in R/R MM

Addition of Daratumumab to Lenalidomide Maintenance Boosts MRD-Negative Conversions in Myeloma Following ASCT

Apalutamide Boosts 24-Month OS in Real-World Population With Metastatic Castration-Sensitive Prostate Cancer

View More Latest Conference Coverage

Advertise

About OncLive

Editorial Board

MJH Life Sciences brands

Privacy

Terms & Conditions

Do Not Sell My Information

Contact Info

2 Commerce Drive
Cranbury, NJ 08512

Overview of First-Line Treatment in Diffuse Large B-Cell Lymphoma

EP: 1.Overview of First-Line Treatment in Diffuse Large B-Cell Lymphoma

EP: 2.Evolving Practice Standards and Disease Progression Beyond Frontline Therapy for Patients with DLBCL

EP: 3.Treatment Selection in Second Line R/R DLBCL

EP: 4.Tafasitamab and Lenalidomide for R/R DLBCL

EP: 5.Real-World Outcomes of Tafasitamab-Lenalidomide for Patients with R/R DLBCL

EP: 6.The Role of CAR T-Cell Therapy in R/R DLBCL

EP: 7.Data Updates: CAR T in the ZUMA-7 and TRANSFORM Trials for R/R DLBCL

EP: 8.Clinical Perspectives of CAR T in R/R Diffuse Large B-Cell Lymphoma

EP: 9.Navigating Toxicities in CAR T-Cell Therapy in R/R DLBCL

EP: 10.Relapsed/Refractory DLBCL: Therapeutic Options in the Third Line Setting

EP: 11.Bispecifics for Third Line Therapy of R/R DLBCL

EP: 12.R/R DLBCL: Safety Considerations for Bispecific Antibodies

EP: 13.Treatment Sequencing of Later Line Therapies in R/R DLBCL

EP: 14.Additional Data Updates from ASH 2023

EP: 15.Future Outlooks in the Treatment of R/R DLBCL

Newsletter

Latest CME

18th Annual Interdisciplinary Prostate Cancer Congress® and Other Genitourinary Malignancies

Updates and Innovations in Nonopioid Pain Management Strategies for Breast Cancer Patients Postsurgical Intervention

Community Oncology Connections™: Contextualizing Novel Immunotherapy for Advanced Melanoma – How Do TIL Therapies Fit into Practice? | Arkansas

Community Oncology Connections™: Case Discussions in TNBC…Navigating the Latest Advances and Impact of Disparities in Care | North Carolina

Community Oncology Connections™: Community Oncologists’ Role in Selecting Optimal Oral SERD Treatment for HR+/HER2– Breast Cancer | Minnesota

18th Annual Interdisciplinary Prostate Cancer Congress® and Other Genitourinary Malignancies

Updates and Innovations in Nonopioid Pain Management Strategies for Breast Cancer Patients Postsurgical Intervention

Community Oncology Connections™: Contextualizing Novel Immunotherapy for Advanced Melanoma – How Do TIL Therapies Fit into Practice? | Arkansas

Community Oncology Connections™: Case Discussions in TNBC…Navigating the Latest Advances and Impact of Disparities in Care | North Carolina

Community Oncology Connections™: Community Oncologists’ Role in Selecting Optimal Oral SERD Treatment for HR+/HER2– Breast Cancer | Minnesota

18th Annual Interdisciplinary Prostate Cancer Congress® and Other Genitourinary Malignancies

Updates and Innovations in Nonopioid Pain Management Strategies for Breast Cancer Patients Postsurgical Intervention

Community Oncology Connections™: Contextualizing Novel Immunotherapy for Advanced Melanoma – How Do TIL Therapies Fit into Practice? | Arkansas

Latest Conference Coverage